Last Updated : April 3, 2025
Details
Generic Name:
roflumilast
Project Status:
Pending
Therapeutic Area:
atopic dermatitis
Manufacturer:
Arcutis Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Zoryve
Project Line:
Reimbursement Review
Project Number:
SR0887-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For topical treatment of mild to moderate atopic dermatitis in patients 6 years of age and older, with inadequate response, intolerance, or contraindications to topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For topical treatment of mild to moderate atopic dermatitis in patients 6 years of age and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : April 3, 2025